Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-specific cyclic nucleotide binding in leukemic leukocytes.

T H Weber, J Linkola

    Cancer Letters
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Telemedicine for the International Space Station.

    Acta astronautica·2001
    Same author

    A rapid fluorometric enzyme immunoassay for the determination of neonatal TSH from blood spots.

    Clinica chimica acta; international journal of clinical chemistry·1991
    Same author

    Diagnostic value of cerebrospinal fluid adenosine deaminase determination.

    Scandinavian journal of infectious diseases·1991
    Same author

    Endogenous interference in immunoassays in clinical chemistry. A review.

    Scandinavian journal of clinical and laboratory investigation. Supplementum·1990
    Same author

    Immunocatalytic assay of pancreatic alpha-amylase in serum and urine with a specific monoclonal antibody.

    Clinical chemistry·1989
    Same author

    Adenosine deaminase activity in joint effusions.

    Scandinavian journal of rheumatology·1988
    Same journal

    Chinese Expert Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer (2026 Edition).

    Cancer letters·2026
    Same journal

    Tertiary Lymphoid Structures and Hepatocellular Carcinoma: Guardian and Executioner.

    Cancer letters·2026
    Same journal

    GliomaDeconv Maps Glioma-Specific Cellular Programs from Bulk Transcriptomic Profiles and Reveals Spatiotemporal Associations with Progression and Treatment Response.

    Cancer letters·2026
    Same journal

    RETRACTED: Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells.

    Cancer letters·2026
    Same journal

    FGFR2 Fusion-Driven CXCL3 Downregulation Attenuates Neutrophil Recruitment in Intrahepatic Cholangiocarcinoma.

    Cancer letters·2026
    Same journal

    Dissection of spatial hypoxic and inflammatory ecosystem in glioblastoma.

    Cancer letters·2026
    See all related articles

    Leukemic cells exhibit significantly higher cyclic adenosine monophosphate (cAMP) binding than normal cells. This binding in cancer cells is non-specific, unlike the specific binding observed in healthy or activated leukocytes.

    Area of Science:

    • Biochemistry
    • Cell Biology
    • Cancer Research

    Background:

    • Cyclic adenosine monophosphate (cAMP) plays a crucial role in cellular signaling.
    • Alterations in cAMP binding can be indicative of cellular transformation and disease.

    Purpose of the Study:

    • To investigate and compare the cyclic adenosine monophosphate (cAMP) binding characteristics of normal leukocytes versus malignant leukocytes.
    • To determine if cAMP binding specificity differs between normal and cancerous white blood cells.

    Main Methods:

    • Quantifying cyclic adenosine monophosphate (cAMP) binding capacity per milligram of protein in extracts from leukemic lymphocytes and myelomonocytic cells.
    • Assessing the specificity of cAMP binding by evaluating the cells' ability to discriminate between cAMP and cyclic guanosine monophosphate (cGMP).

    Related Experiment Videos

  • Comparing cAMP binding in normal lymphocytes, mitogen-activated normal lymphocytes, and leukemic cells.

    • Main Results:

    • Leukemic lymphocytes and myelomonocytic cells demonstrated significantly higher cAMP binding capacity compared to normal cells.
    • Malignant leukocytes exhibited non-specific cAMP binding, failing to differentiate effectively between cAMP and cGMP.
    • Activated normal lymphocytes showed increased cAMP binding but retained specific binding characteristics.

    Conclusions:

    • Malignantly transformed leukocytes display a marked non-specificity in cyclic adenosine monophosphate (cAMP) binding.
    • This non-specific cAMP binding in cancer cells contrasts with the specific binding observed in both resting and proliferating normal leukocytes.
    • The findings suggest potential differences in cellular regulation and signaling pathways between normal and cancerous leukocytes.